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ABSTRACT 
PURPOSE: 
Oxaliplatin forms part of routine treatment for advanced colorectal cancer (aCRC); 
however, it often causes severe peripheral neuropathy resulting in treatment 
discontinuation. We sought to determine the molecular and cellular mechanism 
underlying this toxicity. 
 
PATIENTS AND METHODS: 
We exome resequenced blood DNA samples from nine aCRC patients who had 
severe peripheral neuropathy associated with oxaliplatin (PNAO) within 12 weeks of 
treatment. We Sanger sequenced the ERCC4 and ERCC6 open reading frames in 
63 patients with PNAO and carried out targeted genotyping in 1,763 patients without 
PNAO. We tested the functionality of ERCC4 variants using viability and DNA repair 
assays in Schizosaccharomyces pombe and human cell lines after exposure to 
oxaliplatin and UV light. 
 
RESULTS: 
Exome resequencing identified one patient carrying a novel germline truncating 
mutation in the nucleotide excision repair (NER) gene ERCC4. This mutation was 
functionally-associated with sensitivity to oxaliplatin (P=3.5x10-2). We subsequently 
found that multiple rare ERCC4 nonsynonymous variants were overrepresented in 
affected individuals (P=7.7x10-3) and three of these were defective in the repair of 
UV light-induced DNA damage (P<1x10-3). We validated a role for NER genes in 
PNAO by finding that multiple rare ERCC6 nonsynonymous variants were similarly 
overrepresented in affected individuals (P=2.4x10-8). Excluding private variants, 
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22.2% (14/63) of patients with PNAO carried Pro379Ser or Glu875Gly in ERCC4, or, 
Asp425Ala, Gly446Asp or Ser797Cys in ERCC6, as compared to 8.7% (152/1,750) 
of unaffected patients (OR=3.0, 95% CI 1.6-5.6, P=2.5x10-4). 
 
CONCLUSIONS: 
Our study provides evidence for a role of NER genes in oxaliplatin-induced 
peripheral neuropathy, together with mechanistic insights.  
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INTRODUCTION 
Oxaliplatin, a third-generation platinum drug, in combination with 5-fluorouracil and 
leucovorin (FL), or oral capecitabine, is standard treatment for locally advanced and 
metastatic colorectal cancer (CRC); it improves both response and progression-free 
survival.1,2 It also improves disease-free survival in the adjuvant treatment of stage II 
and III colon cancer patients.3 In addition, oxaliplatin is widely used to treat other 
gastrointestinal malignancies. Platinum agents exert their effects by forming inter- 
and intra-strand DNA cross-links,4 which stall the cell cycle, inhibit DNA synthesis5 
and trigger apoptosis.6 Oxaliplatin also induces oxidative DNA damage.7 
 
Peripheral neuropathy is a well-recognised dose-limiting toxicity of oxaliplatin.8,9 High 
cumulative doses are associated with chronic peripheral nerve damage causing 
sensory ataxia and functional impairment.10 Chronic sensory neuropathy has been 
observed in around half of patients who received oxaliplatin with infusional FL.11 
Importantly, it is neurotoxicity, rather than tumour progression, which is often the 
cause of treatment discontinuation.12 Since neurotoxicity is not correlated with 
response,12 it is considered a potentially avoidable side effect. The underlying cause 
of peripheral neuropathy is not known, although oxidative stress may be a 
contributing factor.13-15 
 
Although numerous genetic associations with peripheral neuropathy have been 
proposed (GSTP1,16-19 AGXT,20 ERCC1,21,22 FARS2,22 TAC1,22 SCN10A,23 
SCN4A,23 VAC14,24 together with several genome-wide associated loci25,26), none 
have been independently validated and introduced into patient stratification. 
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Here, we sought to delineate the underlying cause by exome resequencing patients 
with severe peripheral neuropathy after treatment with oxaliplatin-based 
chemotherapy. 
 
MATERIALS AND METHODS 
Patients 
We analysed blood DNA samples from unrelated patients with advanced CRC 
(aCRC) from the UK national trial COIN (NCT00182715).27 Patients were 
randomised to receive continuous oxaliplatin and fluoropyrimidine chemotherapy, 
continuous chemotherapy plus cetuximab, or intermittent chemotherapy. In all 
patients, treatment was identical for the first 12 weeks apart from the choice of 
fluoropyrimidine together with the randomisation of ± cetuximab. All patients gave 
fully informed consent for their samples to be used for bowel cancer research 
(approved by REC [04/MRE06/60]). We obtained the maximum grade of peripheral 
neuropathy after 12 weeks of treatment. Patients with grade 3/4 peripheral 
neuropathy or that had had oxaliplatin-dose reduction due to severe peripheral 
neuropathy were classified as suffering from peripheral neuropathy associated with 
oxaliplatin (PNAO). Patients with no, or grade 1, peripheral neuropathy formed a 
control group and were classified as not having PNAO. Patients with grade 2 
peripheral neuropathy were excluded to allow a better discrimination between the 
two patient groups. 
 
Molecular analyses 
We excluded known inherited neuropathies by carrying out multiplex ligation-
dependent probe amplification analysis of PMP22 (~75% of patients with Charcot-
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Marie-Tooth syndrome, the most common form of inherited neuropathy, have a 
1.4MB duplication) and by examining the exome resequencing data for PMP22 and 
65 other genes associated with rare inherited neuropathies (Supplemental Materials 
and Methods). 
 
Library fragments containing exomic DNA were collected using the Roche 
Nimblegen SeqCap EZ Exome Library solution-based method. Massively parallel 
sequencing was performed on the Illumina Genome Analyser. On average, across 
the exome, we had 55% (range 46-60%) coverage of the open reading frame (ORF) 
at 20-fold depth. Fastq files were processed through a sequence analysis pipeline 
using BWA for sequence alignment and modules from the Broad Institute’s Genome 
analysis Toolkit to recalibrate quality scores, refine alignments around potential 
insertions/deletions (indels), eliminate duplicate reads, call indel and SNP 
genotypes, generate QC metrics and apply quality filters to the genotype calls. SNP 
calls were annotated using ANNOVAR. PCR and Sanger sequencing were carried 
out as described in Supplemental Materials and Methods. ERCC4 and ERCC6 
nonsynonymous variants were genotyped using KASPar (LGC) or BeadArray 
(Illumina) technologies (Supplemental Materials and Methods). 
 
Functional analyses 
Production of a Schizosaccharomyces pombe rad16 base strain, the rad16 wild type 
vector, Cre recombinase mediated cassette exchange, transformation of the base 
strain, site-directed mutagenesis and treatment with oxaliplatin and UV light was 
carried out as described in Supplemental Materials and Methods. 480 EBV-
transformed human lymphoblastoid cell lines established from healthy Caucasian 
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individuals (ECACC, Salisbury) were assayed for the ERCC4 variants Pro379Ser, 
Arg576Thr and Glu875Gly using KASPar (LGC). Three cell lines for each variant in a 
heterozygous state and wild type controls (n=3) were selected for the functional 
analyses. Cell lines were established in RPMI 1640 supplemented with 10% foetal 
bovine serum, penicillin/streptomycin and L-glutamine and maintained at 37ºC and 
5.0% CO2. Survival analyses were carried out as described in Supplemental 
Materials and Methods. For DNA repair assays, cells were irradiated with 70J UV-C 
and aliquots removed at 0, 4, 24 and 48 hours after treatment, sorted by FACS for 
viable cells, and DNA extracted. DNA samples were probed for CPDs using an 
ELISA kit (Cell BioLabs) and absorbance was read at 450nm using a plate reader, 
with a reference range of 620nm (Supplemental Materials and Methods). 
 
Statistical and bioinformatic analyses 
For association analyses, R v.3.3.2 was used for the Pearson's Chi-squared test or 
Fishers exact test, where appropriate. Average survival data for oxaliplatin and UV 
light exposure in S.pombe was normalised to wild type and analysed using SPSS 
v.23 ANOVA with Dunnett correction (following transformation using the arcsine 
function). For DNA repair assays, statistical analyses were performed in SPSS using 
a two-way ANOVA, with mutation status and treatment as the independent variables. 
The dependent variable was CPD quantification (ng/ml) as a measure of DNA repair. 
Individual ANOVAs were run at 24 and 48 hours. In silico predictions for functional 
significance of nonsynonymous variants were determined using Align-Grantham 
Variation/Grantham Deviation (Align-GVGD). Linkage disequilibrium (LD) was 
obtained using Haploview v.4.2. 
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RESULTS 
Of the 2,445 patients with aCRC in the COIN trial, 23% of those that received 
oxaliplatin and fluorouracil-based therapy and 16% of those that received oxaliplatin 
and capecitabine-based therapy had severe (≥ grade 3) peripheral neuropathy over 
the course of the trial.27 We focussed on patients with severe PNAO within the first 
12 weeks of treatment (Supplemental Materials and Methods and Table 1) as a 
potentially enriched group for causal germline mutations (n=63 patients). Although 
fewer of these patients responded to treatment at 12 weeks (47%, 26/55 with 
response data; Table 1) as compared to patients without PNAO (grade ≤1, n=1,763; 
57%, 884/1542 with response data), this was not statistically significant (P=0.14). 
 
Nine of the 63 patients with severe PNAO had exome resequencing of their germline 
blood DNA samples. These patients were selected based on review of their medical 
notes and had no potential confounding clinical complications. We identified on 
average 48 (range 40-56) stop gains and 88 (73-111) indels predicted to result in 
frameshift mutations, per patient exome (Supplemental Table). We excluded known 
inherited neuropathies in these patients by PMP22 dosage analysis and by 
examining the resequencing data for 66 candidate genes (no stop gains or truncating 
indels were predicted). 
 
Novel truncating mutation in ERCC4 
Variants not present in dbSNP v.132 (assigned as novel) were considered most 
likely to cause PNAO; we identified on average 8 (range 2-11) and 28 (16-57) novel 
stop gains and frameshifting indels, respectively, per patient (Supplemental Table). 
We also considered that germline truncating mutations in genes involved in 
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oxaliplatin transport, metabolism or the repair of its associated damage might be 
responsible for PNAO; we identified 104 such genes from literature reviews 
(Supplemental Materials and Methods). All nine patients carried truncating variants 
in these selected genes (range 1-4); however, only one of these variants, in a single 
patient, was novel (Supplemental Table). Patient 8 carried the novel stop gain 
Ser613X in the nucleotide excision repair (NER) gene ERCC4, which was confirmed 
by Sanger sequencing of an independent PCR product (Supplemental Table). We 
did not find any other coding region variants in the second ERCC4 allele in Patient 8 
after direct sequence analysis of their entire ORF and flanking intronic sequences. 
Clinical review confirmed that this patient did not have xeroderma pigmentosum (XP) 
(caused by bi-allelic ERCC4 mutations). 
 
We carried out a more comprehensive analysis of all known DNA repair genes 
(REPAIRtoire, n=163 genes, http://repairtoire.genesilico.pl/,28 and, MD Anderson / 
Wood’s DNA repair list, n=244 genes, 
https://www.mdanderson.org/documents/Labs/Wood-Laboratory/human-dna-repair-
genes.html,29), including those in the base excision repair system that repair 
oxidative DNA damage,30 but did not find any further novel stop-gains or truncating 
indels. 
 
Functional analysis of the ERCC4 stop mutation 
We investigated whether the ERCC4 nonsense mutation induced sensitivity to 
oxaliplatin and UV light (causes cyclobutane pyrimidine dimers [CPDs] that are 
repaired by NER). We re-created the mutation in the Schizosaccharomyces pombe 
homolog rad16 (Ser585X) in a base strain and a strain deficient in endonuclease 
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uve1 (a pombe-specific alternative UV light repair system). Following oxaliplatin 
treatment, we observed decreased survival for rad16-Ser585X (P=3.5x10-2) in 
comparison to wild type rad16 (rad16+), and in a similar range to a control rad16 
deleted mutant (rad16Δ) (Fig.1A). Similarly, we observed decreased survival of 
uve1Δ-rad16-Ser585X following treatment with UV light (P<1x10-3) (Fig.1B). 
 
Multiple rare ERCC4 variants associated with peripheral neuropathy 
We sought further evidence for a role of ERCC4 in PNAO and Sanger sequenced the 
ERCC4 ORF and flanking intronic sequences in all 63 patients with PNAO. We did 
not find any further stop gains or truncating indels; however, we did identify four rare 
(minor allele frequencies <5% in dbSNP) nonsynonymous variants (Pro379Ser, 
rs1799802, in 3 patients; His466Gln, rs372950439, in 1 patient; Arg576Thr, 
rs1800068, in 1 patient; Glu875Gly, rs1800124, in 4 patients) (Table 1). Pro379Ser, 
Arg576Thr and Glu875Gly were predicted to interfere with function (Table 2). We also 
identified one common nonsynonymous (Arg415Gln, rs1800067), three synonymous 
and three 5’ untranslated region (UTR) variants. We genotyped the ERCC4 
nonsynonymous variants in all COIN patients with available samples. His466Gln was 
not seen in any further patients. Each of the other rare variants were found more 
frequently in cases with, as compared to those without, PNAO (Table 2). Combined, 
significantly more patients with PNAO carried one of these variants (13.1% [8/61] as 
compared to 5.2% [87/1,671] of patients without PNAO; P=7.7x10-3). 
 
The common variant Arg415Gln was found in similar proportions of patients with 
(14.3% [9/63]) and without (14.8% [260/1,754]) PNAO (P=0.87). An intronic variant in 
ERCC4 (rs1799800), associated with late onset bortezomib-associated neuropathy31, 
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was not associated with PNAO (found in 38.1% of patients with PNAO as compared 
to 48.0% without, P=0.12). 
 
Functional analysis of ERCC4 nonsynonymous variants 
We sought evidence for causal effects of Pro379Ser, Arg576Thr and Glu875Gly 
using EBV-transformed human lymphoblastoid cell lines established from healthy 
individuals that carried each variant in a heterozygous state (n=3 for each variant 
and wild type controls). Although treatment with UV light reduced viability in all lines, 
we did not observe any differences between wild type and variant cell lines (data not 
shown). In terms of repair capacity after DNA damage with UV light, all wild type cell 
lines showed noticeable repair 24 hours after treatment, with the majority of CPDs 
being repaired by 48 hours (Fig.2). In contrast, all three sets of variant cell lines 
displayed reduced repair in the initial (P<1x10-3 at both 24 and 48hours) and 
validation (P<1x10-3 at both 24 and 48hours) experiments (Fig.2). 
 
Validated role for NER in PNAO 
We attempted to validate a role for NER gene defects in PNAO and sought novel 
nonsynonymous variants in all ERCC gene family members by re-analysing the 
exome resequencing data. We identified Gly929Arg in ERCC6 in one patient, which 
was confirmed using an independent PCR product. We sought further potentially 
causal ERCC6 variants by direct sequence analysis of the ORF, intronic boundaries 
and 5’UTR in all 63 patients with PNAO. We identified nine rare (Table 1) and five 
common nonsynonymous variants, two synonymous variants and one 5’UTR variant; 
we genotyped nonsynonymous variants in all available cases. Seven rare 
nonsynonymous variants were predicted to be damaging (C55-C65), three of which 
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(Asp425Ala, Pro694Leu and Ser797Cys) were individually overrepresented in 
patients with PNAO (Table 3). Combined, rare ERCC6 nonsynonymous variants 
were highly associated with peripheral neuropathy (in 20.6% [13/63] of patients with 
PNAO as compared to 4.7% [82/1749] of patients without, P=2.4x10-8) (Table 3). 
 
No common ERCC6 nonsynonymous variants were associated with PNAO: 
Gly399Asp was in (patients with, versus those without, PNAO) 27.0% versus 30.7%, 
P=0.54; Arg1213Gly in 36.5% versus 34.6%, P=0.76; Arg1230Pro in 22.2% versus 
19.3%, P=0.57; and, Gln1413Arg in 36.5% versus 34.5%, P=0.74. 
 
Combined analyses of ERCC4 and ERCC6 
Since private variants may skew statistical associations, we considered only rare 
ERCC4 and ERCC6 nonsynonymous variants that were present in ≥2 patients with 
PNAO. In total, 22.2% of patients with PNAO carried Pro379Ser or Glu875Gly in 
ERCC4, or, Asp425Ala, Gly446Asp or Ser797Cys in ERCC6, as compared to 8.7% 
of unaffected patients (OR=3.0, 95% CI 1.6-5.6, P=2.5x10-4) (Table 4). 
 
DISCUSSION 
The rare variant hypothesis predicts that individually rare, but collectively common, 
inherited variants play a significant role in disease susceptibility.32 For example, rare 
nonsynonymous variants in the genes encoding apolipoprotein A1, the adenosine 
triphosphate binding cassette transporter A1 and lecithin cholesterol acyltransferase, 
are over-represented in individuals with low plasma levels of high-density lipoprotein 
cholesterol, a major risk factor for coronary atherosclerosis.33 Furthermore, multiple 
rare nonsynonymous variants in APC play a significant role in inherited 
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predisposition to colorectal adenomas.34 Here, after identifying a novel ERCC4 
truncating mutation in a patient with PNAO, we found that multiple rare ERCC4 and 
ERCC6 nonsynonymous variants were over-represented in affected individuals. 
Therefore, the rare variant hypothesis may also be applicable to germline 
susceptibility to toxicity from therapy. If validated by others, the ERCC4 and ERCC6 
nonsynonymous variants described herein would be considered ‘moderately’ 
penetrant risk alleles for oxaliplatin-induced peripheral neuropathy, as a proportion of 
carriers did not have PNAO within 12 weeks of treatment. 
 
ERCC4 forms a complex with ERCC1, which carries out 5’ incision of damaged DNA 
in NER, the main repair pathway involved in the removal of bulky and DNA-distorting 
adducts.35 The complex has also been implicated in interstrand crosslink (ICL) 
repair36 and in the repair of double strand breaks.37 ERCC6 encodes CSB, a 
SWI/SNF DNA-dependent related ATPase;38 it is recruited to areas of DNA damage 
following stalling of RNA polymerase II and has multiple roles including chromatin 
remodelling39 and recruitment of other NER proteins.40 Given that ERCC4 and 
ERCC6 are likely targets of peripheral neuropathy-associated nonsynonymous 
variants, thorough examination of other NER genes is warranted to determine 
whether they play similar roles in toxicity to oxaliplatin. 
 
Our finding that NER genes may play a role in oxaliplatin-induced peripheral 
neuropathy, is supported by observations from several other studies. Firstly, patients 
with XPA, XPC, XPG and Cockayne syndrome related disorders (caused by biallelic 
ERCC mutations) suffer from peripheral neuropathy prior to treatment.41 The majority 
(17/20) of our ERCC4 or ERCC6 carriers had only one locus-specific mutant allele, 
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and, to our knowledge, none had XP or Cockayne syndrome group B, suggesting 
that haploinsufficiency for a mutant allele may be sufficient to induce peripheral 
neuropathy upon exposure to oxaliplatin. Secondly, an Ercc1-/Δ murine model, which 
has reduced expression of the ERCC4-ERCC1 complex, develops accelerated 
spontaneous peripheral neurodegeneration with significant structural alterations of 
the sciatic nerves.42 Third, in Xpa-/- and Xpc-/- mice, chronic exposure to cisplatin 
resulted in an accelerated accumulation of unrepaired ICLs in neuronal cells.43 
Furthermore, the augmented adduct levels in dorsal root ganglion cells of these mice 
coincided with an earlier onset of peripheral neuropathy-like functional disturbance of 
their sensory nervous system. 
 
Few predictive biomarkers for toxicity to therapy in the treatment of CRC have been 
independently validated. Two rare variants in DPYD have been associated with 
severe toxicity in patients receiving 5-FU44 and a polymorphism in UGT-1A has been 
linked to a higher risk of developing irinotecan-associated neutropenia and 
diarrhea;45 however, none of these biomarkers have been introduced into routine 
clinical practice due to their poor sensitivity and specificity. Here, we identified roles 
for NER gene variants in toxicity to oxaliplatin, which, if validated, may represent an 
opportunity for patient stratification. 
 
ACKNOWLEDGEMENTS 
We thank Simon Reed and Edgar Hartsuiker for helpful advice and Shelley 
Idziaszczyk, Rebecca Williams, Marc Naven and Christopher Smith for technical 
support. 
 
16 
 
AUTHOR CONTRIBUTIONS 
JPCheadle obtained funding for this study. The study was designed by JPCheadle 
with input from MJW, HLM, TSM, RAA, MC, HW, and OF, and was carried out under 
the direction of JPCheadle. JPColley undertook the exome resequencing under the 
guidance and facilities of MJW and HLM. MJW undertook the exome bioinformatic 
analyses. HW undertook the literature searches, Sanger sequencing, validation 
analyses and genotyping with support from RH. HW carried out the functional 
analyses in S.pombe under the guidance and facilities of OF. MC carried out the 
functional analyses in human cells. HW and MC undertook the statistical analyses. 
TSM was CI of COIN, and, RAA was a COIN trial fellow; both provided clinical 
advice and assistance. RSK managed the COIN trial and, with DF, facilitated access 
to the clinical data. JPCheadle and HW interpreted the data with input from co-
authors. JPCheadle and HW wrote the paper with input from MC, and all authors 
provided comments.  
17 
 
REFERENCES 
1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or 
without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 
2000;18:2938-2947. 
2. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of 
fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with 
previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30. 
3. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and 
leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-
2351. 
4. Brabec V, Kasparkova J. Modifications of DNA by platinum complexes. 
Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Update 
2005;8:131-146. 
5. Johnson NP, Hoeschele JD, Rahn RO, et al. Mutagenicity, cytotoxicity, and 
DNA binding of platinum(II)-chloroammines in Chinese hamster ovary cells. Cancer 
Res 1980;40:1463-1468. 
6. Faivre S, Woynarowski JM. Oxaliplatin effects on DNA integrity and apoptosis 
induction in human tumor cells, in Proceedings of the Annual Meeting of the 
American Association of Cancer Research 1998;39:158, New Orleans, LA. 
7. Afzal S, Jensen SA, Sørensen JB, et al. Oxidative damage to guanine 
nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin. 
Cancer Chemother Pharmacol 2012;69:301-307. 
8. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin 
Pharmacother 2003;4:889-901. 
18 
 
9. Weickhardt A, Wells K, Messersmith W. Oxaliplatin induced neuropathy in 
colorectal cancer. J Oncol 2011;201593 doi:10.1155/2011/201593. 
10. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J 
Neurol 2002;249:9-17. 
11. Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin-induced 
neurotoxicity and the development of neuropathy. Muscle Nerve 2005;32:51-60.  
12. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity 
pharmacogenetics. Mol Cancer Ther 2009;8:10-16. 
13. Di Cesare Mannelli L, Zanardelli M, Failli P, et al. Oxaliplatin-induced 
oxidative stress in nervous system-derived cellular models: could it correlate with in 
vivo neuropathy? Free Radic Biol Med 2013;61:143-150. 
14. Tabassum H, Waseem M, Parvez S, et al. Oxaliplatin-induced Oxidative 
Stress Provokes Toxicity in Isolated Rat Liver Mitochondria. Arch Med Res 
2015;46:597-603. 
15. Carozzi VA, Marmiroli P, Cavaletti G. The role of oxidative stress and anti-
oxidant treatment in platinum-induced peripheral neurotoxicity. Curr Cancer Drug 
Targets 2010;10:670-682. 
16. Grothey A, McLeod HL, Green EM, et al. Glutathione S-transferase P1 I105V 
(GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced 
neurotoxicity. J Clin Oncol 2005;23:suppl 3509. 
17. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients 
with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J 
Clin Oncol 2007;25:1247-1254. 
19 
 
18. Peng Z, Wang Q, Gao J, et al. Association between GSTP1 Ile105Val 
polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-
analysis. Cancer Chemother Pharmacol 2013;72:305-314. 
19. Lecomte T, Landi B, Beaune P, et al. Glutathione S-transferase P1 
polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving 
oxaliplatin-based chemotherapy. Clin Cancer Res 2006;12:3050-3056. 
20. Gamelin L, Capitain O, Morel A, et al. Predictive factors of oxaliplatin 
neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 
2007;13:6359-6368. 
21. Inada M, Sato M, Morita S, et al. Associations between oxaliplatin-induced 
peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J 
Clin Pharmacol Ther 2010;48:729-734. 
22. Oguri T, Mitsuma A, Inada-Inoue M, et al. Genetic polymorphisms associated 
with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal 
cancer. Int J Clin Pharmacol Ther 2013;51:475-481. 
23. Argyriou AA, Cavaletti G, Antonacopoulou A, et al. Voltage-gated sodium 
channel polymorphisms play a pivotal role in the development of oxaliplatin-induced 
peripheral neurotoxicity: Results from a prospective multicenter study. Cancer 
2013;119:3570-3577. 
24. Hertz DL, Owzar K, Lessans S, et al. Pharmacogenetic Discovery in CALGB 
(Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that 
Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res 2016;22:4890-
4900. 
20 
 
25. Won HH, Lee J, Park JO, et al. Polymorphic markers associated with severe 
oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 
2012;118:2828-2836. 
26. Dolan ME, El Charif O, Wheeler HE, et al. Clinical and Genome-Wide 
Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset 
Cancer. Clin Cancer Res 2017;23:5757-5768. 
27. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to 
oxaliplatin-based first-line combination chemotherapy for treatment of advanced 
colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 
2011;377:2103-2114. 
28. Milanowska K, Krwawicz J, Papaj G, et al. REPAIRtoire – a database of DNA 
repair pathways. Nucleic Acids Res 2011;39:D788-792. 
29. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res 
2005;577:275-283. 
30. Preston TJ, Henderson JT, McCallum GP, et al. Base excision repair of 
reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the 
cytotoxicity of platinum anticancer drugs. Mol Cancer Ther 2009;8:2015-2026. 
31. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy 
associated with bortezomib and vincristine in patients with newly diagnosed multiple 
myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. 
Lancet Oncol 2010;11:1057-1065. 
32. Fearnhead NS, Winney B, Bodmer WF. Rare variant hypothesis for 
multifactorial inheritance: susceptibility to colorectal adenomas as a model. Cell 
Cycle 2005;4:521-525. 
21 
 
33. Cohen JC, Kiss RS, Pertsemlidis A, et al. Multiple rare alleles contribute to 
low plasma levels of HDL cholesterol. Science 2004;305:869-872. 
34. Azzopardi D, Dallosso AR, Eliason K, et al. Multiple rare non-synonymous 
variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. 
Cancer Res 2008;68:358-363. 
35. Reardon JT, Vaisman A, Chaney SG, et al. Efficient nucleotide excision repair 
of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) 
(JM216) platinum intrastrandDNA diadducts. Cancer Res 1999;59:3968-3971. 
36. Kuraoka I, Kobertz WR, Ariza RR, et al. Repair of an interstrand DNA cross-
link initiated by ERCC1-XPF repair/recombination nuclease. J Biol Chem 
2000;275:26632-26636. 
37. Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease 
facilitates DNA double-strand break repair. Mol Cell Biol 2008;28:5082-5092. 
38. Troelstra C, van Gool A, de Wit J, et al. ERCC6, a member of a subfamily of 
putative helicases, is involved in Cockayne's syndrome and preferential repair of 
active genes. Cell 1992;71:939-953. 
39. Citterio E, Van Den Boom V, Schnitzler G, et al.  ATP-dependent chromatin 
remodeling by the Cockayne syndrome B DNA repair-transcription-coupling factor. 
Mol Cell Biol 2000;20:7643-7653. 
40. Fousteri M, Vermeulen W, van Zeeland AA, et al. Cockayne syndrome A and 
B proteins differentially regulate recruitment of chromatin remodeling and repair 
factors to stalled RNA polymerase II in vivo. Mol Cell 2006;23:471-482. 
41. Kanda T, Oda M, Yonezawa M, et al. Peripheral neuropathy in xeroderma 
pigmentosum. Brain 1990;113:1025-1044. 
22 
 
42. Goss JR, Stolz DB, Robinson AR, et al. Premature aging-related peripheral 
neuropathy in a mouse model of progeria. Mech Ageing Dev 2011;132:437-442. 
43. Dzagnidze A, Katsarava Z, Makhalova J, et al. Repair capacity for platinum-
DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J 
Neurosci 2007;27:9451-9457. 
44. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors 
for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the 
German 5-FU Toxicity Study Group. J Clin Oncol 2008;26:2131-2138. 
45. Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan 
induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290-1295. 
 
 
23 
 
Table 1. Clinical information and, ERCC4 and ERCC6 genotypes, for 63 patients with severe PNAO 
 
ID Age Sex Arm Chemoth
erapy 
Response at 12 
weeks 
Max 
grade 
PN (12 
weeks) 
Oxaliplatin 
stopped 
for 
neurotoxic
ity within 
12 weeks? 
If 
stopped, 
time 
from 
randomis
ation 
(days) 
ERCC4 
 
ERCC6 
Pr
o
37
9S
er
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is
46
6G
ln
 
A
rg
57
6T
hr
 
Se
r6
13
X 
G
lu
87
5G
ly
 
 
A
sp
42
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la
 
G
ly
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6A
s
p 
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o
69
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r7
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ly
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rg
 
Ph
e1
21
7C
ys
 
A
la
12
96
Th
r 
Ph
e1
43
7I
le
 
Th
r1
44
1I
le
 
1 49 F C OxMdG Partial response 3 Y 33 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
2 73 M B XELOX Stable disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n m/n n/n n/n n/n n/n n/n 
3 68 F C XELOX Stable disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
4 72 F A OxMdG Stable disease 3 Y 41 m/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
5 61 M C XELOX Stable disease 3 Y 27 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
6 77 M B XELOX No assessment 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
7 73 M C OxMdG Progressive disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n m/n n/n 
8 77 F A XELOX No assessment 3 
  
n/n n/n n/n m/n n/n 
 
n/n n/n n/n n/n n/n m/n n/n n/n n/n 
9 76 F C XELOX No assessment 3 
  
n/n n/n n/n n/n m/n 
 
n/n n/n n/n n/n m/n n/n n/n n/n n/n 
10 52 F A OxMdG Stable disease 3 Y 59 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
11 62 M C OxMdG Partial response 3 Y 49 n/n m/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
12 59 F C OxMdG Stable disease 3 Y 62 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
13 62 M B XELOX Progressive disease 3 Y 79 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
14 71 F B XELOX Partial response 4 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
15 56 F B XELOX Stable disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
16 48 M B XELOX Progressive disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
17 77 M A XELOX Stable disease 3 Y 79 n/n n/n n/n n/n n/n 
 
m/n n/n n/n n/n n/n n/n n/n n/n n/n 
18 69 M C XELOX Stable disease 3 Y 67 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
19 62 M B XELOX Stable disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
20 69 F A XELOX Partial response 3 Y 64 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
21 65 F A XELOX Stable disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
22 73 F B XELOX Complete response 3 Y 63 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
23 45 F A XELOX Stable disease 3 Y 84 n/n n/n n/n n/n n/n 
 
m/n n/n n/n n/n n/n n/n n/n n/n n/n 
24 57 M A XELOX Stable disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
25 68 M B OxMdG Partial response 3 Y 55 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
26 70 M C XELOX No assessment 3 Y 77 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
27 69 F C XELOX No assessment 3 Y 59 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
28 63 M B XELOX Partial response 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
29 76 F B XELOX Partial response 3 Y 73 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
30 73 M B XELOX Partial response 3 Y 66 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
31 73 F C XELOX Partial response 3 Y 64 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
32 75 M A OxMdG Partial response 3 
  
n/n n/n n/n n/n n/n 
 
n/n m/n n/n n/n n/n n/n n/n n/n n/n 
33 77 F A OxMdG Stable disease 3 Y 76 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
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34 73 F B OxMdG Stable disease 3 Y 54 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
35 40 F A OxMdG Progressive disease 3 Y 52 n/n n/n m/n n/n m/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
36 55 F A OxMdG Stable disease 3 Y 79 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
37 69 F A XELOX Partial response 3 
  
n/n n/n n/n n/n m/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
38 78 M B XELOX No assessment 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
39 67 M C XELOX Partial response 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
40 65 M B OxMdG No assessment 3 Y 78 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
41 69 M B XELOX Stable disease 4 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
42 64 M B XELOX Partial response 3 
  
n/n n/n n/n n/n n/n 
 
n/n m/n n/n n/n n/n n/n n/n n/n n/n 
43 77 F A XELOX Stable disease 3 Y 76 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
44 60 F B XELOX Partial response 3 
  
n/n n/n n/n n/n n/n 
 
m/n n/n n/n m/n n/n n/n n/n n/n n/n 
45 73 M B XELOX Partial response 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n m/n n/n n/n 
46 68 M A XELOX Partial response 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
47 53 F A XELOX Partial response 3 
  
n/n n/n n/n n/n n/n 
 
n/n m/n n/n n/n n/n n/n n/n n/n n/n 
48 73 M B XELOX Complete response 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
49 56 F A XELOX Stable disease 3 
  
n/n n/n n/n n/n m/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
50 40 F C XELOX Partial response 3 Y 63 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
51 65 F A XELOX Stable disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n m/m 
52 67 F B XELOX Stable disease 3 Y 48 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
53 73 M B XELOX Stable disease 3 Y 70 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
54 74 F C XELOX Partial response 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
55 63 F B XELOX Partial response 3 Y 49 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
56 78 M B XELOX Partial response 3 Y 67 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
57 62 F A OxMdG Partial response 3 Y 68 n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
58 61 M A XELOX Stable disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
59 50 F A XELOX Progressive disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
60 74 F C XELOX Progressive disease 3 
  
n/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
61 77 M C OxMdG Partial response 3 Y 55 n/n n/n n/n n/n n/n 
 
n/n n/n m/n n/n n/n n/n n/n n/n n/n 
62 40 M B XELOX No assessment 3 
  
m/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
63 48 M A OxMdG Partial response 3 
  
m/n n/n n/n n/n n/n 
 
n/n n/n n/n n/n n/n n/n n/n n/n n/n 
 
Patients 1-9 were exome resequenced and those highlighted carried variants. COIN Arm A - received continuous oxaliplatin and fluoropyrimidine chemotherapy, Arm B - 
continuous chemotherapy plus cetuximab, Arm C - intermittent chemotherapy. Patients had infusional 5FU or capecitabine as the combination partner with oxaliplatin 
(OxMdG and XELOX, respectively). Abbreviations - PN, peripheral neuropathy; m, mutant; n, normal allele. 
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Table 2 – Rare ERCC4 nonsynonymous and stop-gain variants in patients with 
(+) and without (-) PNAO. 
 
Variant rs number 
aAlign-
GVGD 
score 
Frequency in patients 
X2 P 
+ PNAO - PNAO 
Pro379Ser rs1799802 C65 3/63 (4.8%) 27/1,763 (1.5%) - 0.08 
His466Gln rs372950439 C15 1/61 (1.6%) 0/1,677 (0%) - - 
Arg576Thr rs1800068 C65 1/63 (1.6%) 4/1,762 (0.2%) - 0.16 
Ser613X Novel C65 1/63 (1.6%) - - - 
Glu875Gly rs1800124 C65 4/63 (6.4%) 60/1,763 (3.4%) - 0.28 
       
bTotal 8/61 (13.1%) 87/1,671 (5.2%) 7.1 7.7x10-3 
excluding private variants 7/63 (11.1%) 86/1,763 (4.9%) 4.9 2.7x10-2 
 
aScore of predicted functional impact by Align-Grantham Variation/Grantham 
Deviation (Align-GVGD): C65 – most likely and C15 – less likely to affect function. 
bSer613X was not included in the total since it was only assayed in cases with PNAO; 
one patient with PNAO carried Arg576Thr and Glu875Gly, and another without 
carried Pro379Ser and Glu875Gly. Values reflect the number of patients successfully 
genotyped (totals - for all variants). 
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Table 3 - Rare ERCC6 nonsynonymous variants in patients with (+) and without 
(-) PNAO. 
 
Variant rs number 
aAlign-
GVGD 
score 
Frequency in patients  
X2 P 
+ PNAO - PNAO 
Asp425Ala rs4253046 C65 3/63 (4.8%) 15/1,763 (0.9%) - 0.02 
Gly446Asp rs4253047 C65 3/63 (4.8%) 55/1,750 (3.1%) - 0.45 
Pro694Leu rs114852424 C65 1/63 (1.6%) 0/1,763 (0%) - 0.03 
Ser797Cys rs146043988 C65 2/63 (3.2%) 2/1,763 (0.1%) - 0.01 
Gly929Arg Novel N/A 1/63 (1.6%) 1/1763 (0.1%) - 0.07 
Phe1217Cys rs61760166 C65 1/63 (1.6%) 3/1,763 (0.2%) - 0.13 
Ala1296Thr rs139509516 C55 1/63 (1.6%) 1/1,762 (0.1%) - 0.07 
Phe1437Ile rs758679804 C15 1/63 (1.6%) 3/1,763 (0.2%) - 0.13 
Thr1441Ile rs4253230 C65 1/63 (1.6%) 4/1,763 (0.2%) - 0.16 
 
     
 
bTotal  13/63 (20.6%) 82/1,749 (4.7%) 31.1 2.4x10-8 
excluding private variants  7/63 (11.1%) 71/1,750 (4.1%) 5.7 1.7x10-2 
 
aScore of predicted functional impact: C65 – most likely, C55 – likely, C15 – less 
likely to affect function; N/A – not applicable (alternative transcript). bOne patient with 
PNAO carried Asp425Ala and Ser797Cys, and, one patient without PNAO carried 
Asp425Ala and Gly446Asp, and another carried Gly446Asp and Phe1217Cys. 
Values reflect the number of patients successfully genotyped (totals - for all variants). 
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Table 4 – Combined analysis of non-private, rare ERCC4 and ERCC6 
nonsynonymous variants. 
 
Gene Variants 
Frequency in patients (%) 
X2 
OR 
(95% CIs) P + PNAO - PNAO 
      
 
ERCC4 Pro379Ser, 
Glu875Gly 
7/63 (11.1%) 86/1,763 (4.9%) 4.9 - 2.7x10-2 
      
 
ERCC6 Asp425Ala, 
Gly446Asp, 
Ser797Cys 
7/63 (11.1%) 71/1,750 (4.1%) 5.7 - 1.7x10-2 
      
 
 
aTotal 14/63 (22.2%) 152/1,750 (8.7%) 13.4 3.0 (1.6-5.6) 2.5x10
-4
 
 
aFour patients without PNAO carried Glu875Gly in ERCC4 and Gly446Asp in 
ERCC6 and another carried Pro379Ser in ERCC4 and Gly446Asp in ERCC6. 
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LEGENDS TO FIGURES 
Figure 1. The ERCC4 nonsense mutation induced sensitivity to oxaliplatin and 
UV light in a S. pombe (rad16) model system. Average percentage survival from 
(A) four independent experiments following oxaliplatin treatment, or, (B) three 
independent experiments following treatment with UV light, for a control rad16 gene 
deletion mutant (rad16Δ) and rad16-Ser585X (mimics Ser613X seen in a patient with 
PNAO), normalised to rad16+. For treatment with UV light, all strains were uve1Δ. 
Standard deviations displayed as vertical bars. 
 
Figure 2. ERCC4 nonsynonymous variants displayed reduced repair capacity. 
Average CPD concentrations (ng/ml) after UV-C (70J) irradiation in wild type cells 
and cells carrying (A) Pro379Ser, (B) Arg576Thr and (C) Glu875Gly over a 48hr 
period, showing the initial (top panels) and validation (lower panels) experiments. 
CPD concentrations are plotted as an average of two duplicate samples from the 
same experiment run on separate ELISA plates, which are shown against time with 
standard error bars (data from the wild type cells is shown in A, B and C). The test 
and validation experiments were biological repeats. V = variant cell line; C = wild 
type control cell line; 1-3 = different cell lines. 
